Boston Scientific Corporation develops and markets less invasive medical devices and therapies used by healthcare professionals and institutions globally. News about BSX centers on operating results, business highlights, capital-structure updates and product developments across cardiovascular, respiratory, digestive, oncological, neurological and urological care.
Recurring company updates include clinical evidence and regulatory milestones for platforms such as FARAPULSE pulsed field ablation, WATCHMAN left atrial appendage closure, EKOS endovascular therapy and the Asurys Fluid Management System. Coverage also reflects conference presentations, FDA clearances, trial results and management discussions of quarterly performance across the company’s medical-technology portfolio.
Boston Scientific Corporation (NYSE: BSX) will host a conference call on July 29, 2020, at 8:00 a.m. EDT, to discuss its second-quarter financial results for the period ending June 30, 2020. The call, led by CEO Mike Mahoney and CFO Dan Brennan, will include insights on business highlights. The company plans to release its financial results prior to the call. Investors can access the call and its replay on the Boston Scientific Investor Relations website.
Boston Scientific (NYSE: BSX) has obtained FDA 510(k) clearance for its LUX-Dx™ Insertable Cardiac Monitor (ICM) System, designed to detect arrhythmias related to conditions like atrial fibrillation and cryptogenic stroke. This new device features a dual-stage algorithm for verifying arrhythmias and allows remote programming via the LATITUDE Clarity™ Data Management System. The LUX-Dx ICM can identify key cardiac events and reduces false positives, enhancing clinical decision-making. A limited market release will start immediately, with full launch later this year.